Merete Lund Hetland

Medicin og biovidenskab

1. Rheumatoid Arthritis 100%
2. Antirheumatic Agents 28%
3. Tumor Necrosis Factor Inhibitors 26%
4. Registries 25%
5. Joints 14%
6. Psoriatic Arthritis 14%
7. Adalimumab 14%
8. Methotrexate 12%
9. Anti-Citrullinated Protein Antibodies 11%
10. Cohort Studies 10%
11. Therapeutics 10%
12. Ankylosing Spondylitis 9%
13. Abatacept 9%
14. Arthritis 9%
15. Biological Products 8%
16. Magnetic Resonance Imaging 8%
17. Infliximab 8%
18. Rheumatic Diseases 7%
19. Biosimilar Pharmaceuticals 7%
20. Randomized Controlled Trials 7%
21. Synovitis 7%
22. Pharmaceutical Preparations 7%
23. Rheumatology 7%
24. tocilizumab 6%
25. Observational Studies 6%
26. Inflammation 5%
27. Rituximab 5%
28. Tumor Necrosis Factor-alpha 5%
29. Joint Diseases 5%
30. Denmark 5%
31. Patient Reported Outcome Measures 5%
32. Etanercept 5%
33. secukinumab 5%
34. Bone and Bones 5%